8,760
+2.70%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Boryung
Its shares trade on KRX under the ticker 003850.KS. It has been listed since 24 October 1988. In the fiscal year to 31 December 2025, it reported revenue of ₩1.02trn and net income of ₩64.30bn. At that date it held total assets of ₩1.39trn and shareholders' equity of ₩845.50bn.
Boryung Corp. engages in the manufacture of of drug products. The company is headquartered in Seoul, Seoul. The firm mainly manufactures and distributes pharmaceutical products including antihypertensive drugs, gastrointestinal disorder drugs, antibiotics, gastric ulcer drugs, oral antibiotics, anticancer drugs and antihyperlipidemic drugs, among others. The firm distributes its products in domestic and overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 24 Oct 1988
- Website
- boryung.co.kr ↗
Leadership
Pay as last reported
- Mr. Jeong Gyun KimChairman of the Board, Chief Executive Officer, since 2025₩563.2m
- Mr. Jong Rae YimVice President
- Mr. Min Je BaeManaging Director
- Mr. Seong Won ChoiManaging Director
- Mr. Wung Je JungManaging Director
- Mr. Bong Seok KimManaging Director
- Mr. Yeong Seok KimManaging Director, since 2023
- Ms. Gyeong Suk ParkManaging Director, since 2023
- Mr. Seong KimChief Strategy Officer, Director₩603.9m
- Ms. Eun Ah BaekAssistant Managing Director
- Mr. Seong Nam CheonAssistant Managing Director
- Mr. Yong Gyu GwakInternal Auditor
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Boryung Corp has built a strong reputation in the market due to its commitment to quality and innovation. This reputation helps the company gain customer trust and loyalty.
- With a wide range of products across various therapeutic areas, Boryung Corp has a diversified product portfolio that reduces dependency on a single product or market segment.
Weaknesses
- Boryung Corp's operations are primarily concentrated in the domestic market, limiting its global reach and potential for international growth.
- The company heavily relies on a few key markets for a significant portion of its revenue, making it vulnerable to market-specific risks and fluctuations.
Opportunities
- Expanding into emerging markets presents an opportunity for Boryung Corp to tap into growing customer demand and potentially increase its market share.
- Leveraging advancements in technology can enable Boryung Corp to develop innovative products, improve operational efficiency, and gain a competitive edge in the industry.
Threats
- The pharmaceutical industry is highly competitive, and Boryung Corp faces threats from existing competitors as well as new entrants in the market.
- Compliance with stringent regulations and changing government policies poses a threat to Boryung Corp's operations, requiring constant monitoring and adaptation.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.